We have characterized ADAMTS7B, the authentic fulllength protein product of the ADAMTS7 gene. ADAMTS7B has a domain organization similar to that of ADAMTS12, with a total of eight thrombospondin type 1 repeats in its ancillary domain. Of these, seven are arranged in two distinct clusters that are separated by a mucin domain. Unique to the ADAMTS family, ADAMTS7B is modified by attachment of the glycosaminoglycan chondroitin sulfate within the mucin domain, thus rendering it a proteoglycan. Glycosaminoglycan addition has potentially important implications for ADAMTS7B cellular localization and for substrate recognition. Although not an integral membrane protein, ADAMTS7B is retained near the cell surface of HEK293F cells via interactions involving both the ancillary domain and the prodomain. ADAMTS7B undergoes removal of the prodomain by a multistep furin-dependent mechanism. At least part of the final processing event, i.e. cleavage following Arg 220 (mouse sequence annotation), occurs at the cell surface. ADAMTS7B is an active metalloproteinase as shown by its ability to cleave ␣ 2 -macroglobulin, but it does not cleave specific peptide bonds in versican and aggrecan attacked by ADAMTS proteases. Together with ADAMTS12, whose primary structure also predicts a mucin domain, ADAMTS7B constitutes a unique subgroup of the ADAMTS family.
The extracellular matrix (ECM) 1 is an information-rich assembly influencing cell proliferation, apoptosis, and cell migration. Proteases have an essential role in modulating the environmental cues that ECM provides for tissue morphogenesis, homeostasis, and disease progression. Metalloproteases, especially matrix metalloproteases, have a conspicuous role in ECM degradation as well as in proteolysis of cell-surface and soluble proteins (1, 2) . Another metalloprotease family, ADAM (a disintegrin and metalloprotease domain), contains transmembrane enzymes with a major role in ectodomain shedding of cell-surface molecules, but a negligible function in ECM proteolysis (3) . The active site of ADAM proteases, unlike that of the matrix metalloproteases, is of the reprolysin (snake venom zinc metalloprotease) type (3) . The recent discovery of the ADAMTS (a disintegrin-like and metalloprotease domain with thrombospondin type 1 motif) family brought to light metalloproteases that contain a reprolysintype catalytic site, but, unlike the ADAM proteases, are secreted enzymes with a prominent role in ECM proteolysis.
ADAMTS proteases have a characteristic modular structure whose hallmark is the presence of one or more thrombospondin type 1 repeats (TSRs) (4) . In the short period of time since the discovery of ADAMTS1 in 1997 (4), important functions have been attributed to a number of family members, and mutations of two of these enzymes have been shown to cause human genetic disorders. Inactivating mutations of ADAMTS13 cause inherited thrombocytopenic purpura due to a failure to process von Willebrand factor (5) . Mutations of ADAMTS2, a procollagen aminopropeptidase, cause skin fragility in a variety of mammals, including humans, through failure of incompletely processed collagen to form proper fibrils (6) . ADAMTS2, ADAMTS3, and AD-AMTS14 form a subfamily of procollagen aminopropeptidases (7, 8) . Other ADAMTS enzymes (e.g. ADAMTS1, ADAMTS4, AD-AMTS5, and ADAMTS9) may mediate aggrecan degradation in arthritis and the turnover of the related proteoglycans versican and brevican in blood vessels and the nervous system, respectively (9 -14) . Adamts1 null mice have abnormal adipogenesis, defective angiogenesis in the adrenal gland, and altered ureteric ECM turnover (15) . ADAMTS1 inhibits angiogenesis by its ability to sequester the vascular endothelial growth factor (16) . A mutation in Adamts20 gave rise to the mouse mutant Belted, which has defects in skin pigmentation owing to presumed effects on melanoblast migration (17) . Although progress in this field has been rapid, the properties and functions of the majority of the 19 ADAMTS proteases remain unknown, and we refer to these as orphan enzymes (i.e. without a cognate substrate). ADAMTS7 2 was originally identified as an enzyme containing two TSRs and having a similar domain structure to ADAMTS5, ADAMTS6, and ADAMTS8 (18) . In this work, we describe a longer form of ADAMTS7 (designated ADAMTS7B) that we believe is the authentic full-length version of this enzyme and that suggests that our previous characterization of the C terminus of ADAMTS7 may have been incomplete. The primary structure of ADAMTS7B presented here places this enzyme in a distinct phylogenetic clade with ADAMTS12 (19) . In addition, we have undertaken a detailed characterization of ADAMTS7B with emphasis on its unusual post-translational modification. ADAMTS7B is shown to contain a mucin domain within which is attached one or more chondroitin sulfate chains. This suggests that ADAMTS7B may exist in some cells and tissues as a proteoglycan, with potentially important functional consequences. In addition, we have characterized the maturation of the ADAMTS7B zymogen, demonstrated that the zymogen and mature enzyme may be cell-associated through different mechanisms, and shown that the mature enzyme and possibly the zymogen are active proteases.
EXPERIMENTAL PROCEDURES
Materials-Reagents and chemicals were purchased from Sigma unless otherwise stated.
cDNA Cloning of Mouse ADAMTS7B-A partial cDNA encoding the 290 C-terminal amino acids of ADAMTS7B along with ϳ200 bp of 3Ј-untranslated sequence was isolated from an embryonic day 17 mouse cDNA library (Clontech). This fragment was used as a starting point to clone cDNAs encoding the entire 1641-amino acid open reading frame (ORF) using the original library plus 5Ј-rapid amplification of cDNA ends of RNA from 13-and 17-day-old mouse embryos and Sol8 mouse myotubes. All sequences were verified by isolation of independent duplicate clones. To confirm the continuity of the clones and to generate an expression plasmid, primers from the 5Ј-and 3Ј-ends were used to amplify the entire ORF using cDNA obtained from C2C12 mouse myotubes.
Northern Blot Analysis-Northern blots containing poly(A) ϩ RNA (1 g/lane) from mouse embryos and adult human tissues (BD Biosciences) were hybridized to a [␣- 32 P]dCTP-labeled Adamts7b probe, followed by autoradiographic exposure for 7 days.
Human and Mouse ADAMTS7 Expression Plasmids-For PCR amplification of full-length mouse ADAMTS7B, we used the above mouse plasmid as template and oligonucleotide 5Ј-gaattccaccacattggtgtgcacc-3Ј (with the EcoRI site underlined) as the forward primer and oligonucleotide 5Ј-gcggccgcccgtctggctaccccgctga-3Ј (with the NotI site underlined) as the reverse primer. The fidelity of PCR amplification was confirmed by nucleotide sequencing. For expression of mouse ADAMTS7 PRO-CAT-Myc/His (encoding the signal peptide, prodomain, and catalytic domain, constituting residues 1-444 in mouse ADAMTS7B), PCR amplification was performed utilizing the same forward primer and the reverse primer 5Ј-gtcgacttgagtgcaatgacatccttgg-3Ј (with the SalI site underlined). A critical P1 Arg residue within each of the two major furin cleavage sites in ADAMTS7 PRO-CAT-Myc/His was substituted with Ala (Arg 60 3 Ala and Arg 220 3 Ala) by site-directed mutagenesis (QuikChange site-directed mutagenesis kit, Stratagene). These cDNAs were all cloned into pcDNA3.1(ϩ)-Myc/HisB for expression in-frame with tandem Myc and His 6 tags. The corresponding human catalytic domain construct (encoding residues 1-459) was made by excision from an IMAGE clone (expressed sequence tag N48032) using EcoRI and HindIII and cloning into the matching sites of pcDNA3.1(ϩ)-Myc/HisB. cDNA encoding the mucin domain (mouse Pro 980 -Arg 1366 , named ADAMTS7B FLAG-MUC ) was amplified using mouse ADAMTS7B cDNA as a template with primers 5Ј-aaagcttcccatgtacatagtggaca-3Ј (with the HindIII site underlined) and 5Ј-aggatcctcacctggcaggcagtggat-3Ј (with the BamHI site underlined) and cloned into pCMV9 -3XFLAG for expression with a preprotrypsin leader sequence and three tandem Nterminal FLAG tags.
Transfection and Selection of Stable Cell lines-DNA for transfection was prepared using the Wizard TM purification system (Promega Corp.). 80% confluent HEK293F cells (Invitrogen) in 6-well plates were transfected with 100 ng of ADAMTS7B, ADAMTS7B FLAG-MUC , or human or mouse ADAMTS7 PRO-CAT-Myc/His plasmid using FuGENE 6 (Roche Diagnostics) following the manufacturer's instructions. After 24 h, the medium was changed and supplemented with 1 mg/ml active G418 (Mediatech, Herndon, VA). Discrete clones were isolated using cloning discs (PGC Scientifics, Frederick, MD) and expanded in 24-well plates. Western blotting with anti-c-Myc monoclonal antibody 9E10 or anti-FLAG monoclonal antibody M2 was used to determine the level of protein expression in the media of these clones as appropriate for the plasmid used. The highest expressing clones were expanded to purify human or mouse ADAMTS7 PRO-CAT-Myc/His , full-length mouse ADAMTS7B protein, or mouse ADAMTS7B FLAG-MUC .
Protein Purification and N-terminal Sequence Analysis-HEK293F cells expressing human or mouse ADAMTS7 PRO-CAT-Myc/His were cultured in three-tier flasks (Nunc, Rochester, NY) in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. When cultures were 80% confluent, their medium was replaced with serum-free medium (293 SFM medium, Invitrogen) with subsequent culture at 37°C in the presence of 8% CO 2 for 5 days. The medium was collected, centrifuged to remove cellular debris, and supplemented with NaCl to a final concentration of 0.5 M. ProBond resin (Invitrogen) was prepared by washing with 1 bed volume of binding buffer (0.5 M NaCl and 20 mM sodium phosphate, pH 7.8). The medium and resin were mixed overnight at 4°C (100 l of resin/100 ml of medium). The resin was pelleted by centrifugation at 1500 rpm and then washed five times with 10 volumes of binding buffer. Bound protein was eluted by sequential washes with binding buffer containing 50, 100, 150, 200, and 250 mM imidazole. The washes and eluted protein fractions were assayed for the presence and purity of protein by Coomassie Blue staining. Gels were electroblotted onto polyvinylidene difluoride membrane (Millipore Corp.) for Western blotting. The recombinant protein was detected using anti-c-Myc epitope monoclonal antibody 9E10 or anti-pentahistidine antibody (QIAGEN Inc., Valencia, CA) in conjunction with horseradish peroxidase-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Antibody binding was detected by enhanced chemiluminescence (Amersham Biosciences).
Purification and analysis of full-length mouse ADAMTS7B were essentially similar, except that the cell layer was first washed with 0.5 M NaCl to release the protein from the cell surface; this was pooled with the medium from these cultures and purified and analyzed as described above. Purification of full-length ADAMTS7B was challenging and provided extremely small amounts of substantially purified enzyme such that quantitation could not be done. Since most of the studies with this enzyme were qualitative in nature for determination of its intrinsic characteristics, most assays used sufficient enzyme to permit visualization on Western blots. ADAMTS7B FLAG-MUC was isolated from the conditioned medium of stably transfected cells by affinity purification with anti-FLAG antibody M2-Sepharose beads, following which the beads were extracted in Laemmli sample buffer prior to electrophoresis.
For N-terminal sequencing of human and mouse ADAMTS-7 PRO-CAT-Myc/His , purified protein was electroblotted onto polyvinylidene difluoride membrane and lightly stained with Simply Blue Safe Stain (Invitrogen). The 50-and 29-kDa major bands were excised for amino acid sequencing by Edman degradation on an Applied Biosystems Procise 492 sequencer in the Molecular Biotechnology Core Facility of the Lerner Research Institute. In all the subsequent studies, we used full-length mouse ADAMTS7B or mouse ADAMTS7 PRO-CAT-Myc/His as indicated. No further studies with human ADAMTS7 PRO-CAT-Myc/His beyond the N-terminal sequencing described above were conducted.
Analysis of N-and O-Glycosylation of ADAMTS7B-For enzymatic removal of N-linked carbohydrate with peptide N-glycosidase F (PNGase F), HEK293 cell lysate expressing ADAMTS7B or purified ADAMTS7 PRO-CAT-Myc/His was denatured in 0.5% SDS and 0.1 M ␤-mercaptoethanol at 100°C for 10 min and cooled to room temperature, and Nonidet P-40 was added to a concentration of 1% (v/v) to neutralize the PNGase F inhibitory effects of SDS. The reduced samples were incubated with 100 units of PNGase F (New England Biolabs Inc., Beverly, MA) in 50 mM sodium phosphate, pH 7.5, for 2 h at 37°C. SDS-PAGE and Western blotting (with antibody 9E10) were used to compare in-gel migration with an untreated sample.
For ligand blot analysis, ADAMTS7B FLAG-MUC was electrophoresed on denaturing 10% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride. Horseradish peroxidase-conjugated peanut agglutinin (from Arachis hypogaea) was incubated with the membrane, followed by washes with Tris-buffered saline containing 0.1% Tween 20 and detection by ECL (20, 21) . Enzymatic removal of O-linked carbohydrate was done using a mixture of 10 milliunits of sialidase and 0.5 milliunits of O-glycosidase (Roche Diagnostics) in 50 mM sodium phosphate, pH 7.5, and 0.5% Triton X-100, followed by immunoblotting with anti-FLAG antibody M2. Undigested ADAMTS7B FLAG-MUC was used as a control.
Glycosaminoglycan Analysis-ADAMTS7B and ADAMTS7B FLAG-MUC were treated with 0.5 units of protease-free chondroitinase ABC (Seikagaku America, East Falmouth, MA) in 100 mM Tris and 50 mM sodium acetate, pH 6.5, for 2 h at 37°C. HEK293F, COS-1, and CHO-K1 cell lysates obtained from transiently transfected cells expressing ADAMTS7B were treated with 2.0 units of chondroitinase ABC, 5 units each of keratanase I and II, or 2.5 units each of heparinase I and III in serum-free Dulbecco's modified Eagle's medium for 4 h at 37°C. The proteins from the digests were precipitated with acetone and electrophoresed on reducing 7% SDS-polyacrylamide gel. ADAMTS7B was detected by Western blotting using monoclonal antibodies 9E10 (for ADAMTS7B) and M2 (for ADAMTS7B FLAG-MUC ). Samples untreated with the respective enzymes were used as negative controls. The blots were subsequently stripped by treatment with 62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM 2-mercaptoethanol at 55°C for 30 min. The membrane was reprobed using mouse anti-chondroitin 6-sulfate monoclonal antibody 2035 (Chemicon International, Inc., Temecula, CA), which specifically recognizes stubs with an unsaturated glucuronic acid terminus derived from chondroitin 6-sulfate in chondroitin sulfate proteoglycans following chondroitinase digestion. These stubs are not present in the native undigested chondroitin sulfate proteoglycans.
To further verify the attachment of glycosaminoglycan (GAG) to the ADAMTS7B core protein, we transfected the ADAMTS7B expression plasmid into CHO-K1 cells with a null mutation in ␤-D-xylosyltransferase (CHO-K1 pgsA-745; American Type Culture Collection, CRL-2242) (22) and analyzed the extracts of these cells by Western blotting using monoclonal antibody 9E10. Transfected parental CHO-K1 cells (CCL-61) were analyzed in parallel as a control.
The conditioned medium from HEK293F clones expressing fulllength ADAMTS7B was batch-incubated overnight with heparinSepharose (Bio-Rad) at 4°C with end-over-end rotation. The resin was washed five times with phosphate-buffered saline (PBS) and eluted with increasing concentrations of NaCl (0.2-0.5 M). Uneluted protein was removed by boiling the beads in Laemmli sample buffer. Unbound protein was precipitated with cold acetone. Aliquots of the medium before binding, unbound proteins, and proteins bound to the beads were analyzed by Western blotting with antibody 9E10.
Biosynthesis of ADAMTS7B-QBI 293A cells (Quantum Biotechnologies, Montreal, Canada) were maintained, transiently transfected with mouse ADAMTS7 PRO-CAT-Myc/His using FuGENE 6, and metabolically labeled with a [
35 S]methionine/cysteine mixture (Expre 35 S 35 S, PerkinElmer Life Sciences) essentially as described previously (13) . A 15-min label (pulse) was followed by incubation in complete nonradioactive medium (chase) for various times. Immunoprecipitation with anti-pentahistidine monoclonal antibody was done as described previously (13) . For inhibition of furin, decanoyl-RVKR chloromethyl ketone, a lipid-permeable inhibitor (furin-1 inhibitor; Calbiochem) (23) , was added to HEK293F cells stably expressing ADAMTS7 PRO-CAT-Myc/His at concentrations ranging from 1 to 100 M for 24 h, and the culture medium was analyzed by Western blotting using monoclonal antibody 9E10.
Cotransfection of ADAMTS7B and Proprotein Convertases-CHO RPE.40 cells lacking furin were maintained as described previously (24) . They were transfected with mouse ADAMTS7 PRO-CAT-Myc/His alone (as a control) or in combination with plasmids encoding the proprotein convertases furin, PACE4, PC6B, and PC7. QBI 293A cells were transiently transfected with ADAMTS7 PRO-CAT-Myc/His , also as a control. Cells were metabolically labeled for 3 h, and immunoprecipitation and fluorography of the cell lysate and medium were performed as described (13) .
Cell-surface Biotinylation-Stably transfected HEK293F cells expressing ADAMTS7 PRO-CAT-Myc/His were scraped from plates; washed six times with cold PBS, pH 8.0; and diluted to 2.5 ϫ 10 7 cells/ml. As a control to eliminate all cell-surface proteins, an equal number of cells were treated with trypsin/EDTA for 15 min and washed once with medium containing serum to inactivate trypsin and then six times with cold PBS. 1 ml of each cell suspension was mixed with 0.5 mg of sulfosuccinimidyl 6-(biotinamido)hexanoate (Pierce Biotechnology, Inc.) and incubated for 30 min at room temperature. The cells were pelleted and washed once with 50 mM Tris-Cl, pH 8.0, and three times with PBS, pH 8.0. The cell pellet was lysed in radioimmune precipitation assay buffer (1ϫ PBS, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, and 0.1% (w/v) SDS) at 4°C for 30 min and centrifuged. The soluble portion of the lysate was transferred to a fresh tube and incubated overnight with 50 l of streptavidin-agarose at 4°C with rotation. The streptavidin-agarose was pelleted by centrifugation at 3000 rpm in a microcentrifuge and washed three times in radioimmune precipitation assay buffer and PBS. The supernatant was discarded, and the streptavidin-agarose was resuspended in 50 l of Laemmli buffer and boiled for 5 min. The agarose was pelleted, and the supernatant was loaded onto a 10% SDS-polyacrylamide gel for Western blotting with anti-c-Myc antibody 9E10.
Pulse-Chase Analysis of Cell-surface Biotinylated Proteins-HEK293F monolayers expressing mouse ADAMTS7 PRO-CAT-Myc/His were biotinylated as described above for cell suspensions. The monolayers were washed three times with Tris-buffered saline to inactivate the biotinylation reagent. The monolayers were returned to 10 ml of 293 SFM medium and further cultured for 3 h. 1 ml of medium was taken for analysis at sequential time points, and biotinylated protein was purified from the medium using streptavidin-agarose, followed by Western blotting as described above. Cell lysates were taken at fixed time points to investigate the fate of surface-biotinylated proteins by Western blotting as described above.
␣ 2 -Macroglobulin, Versican, and Aggrecan Processing Assays-To determine whether purified ADAMTS7 PRO-CAT-Myc/His and ADAMTS7B were catalytically active, 5 l of purified full-length ADAMTS7B or ADAMTS7 PRO-CAT-Myc/His was incubated with 5 g of ␣ 2 -macroglobulin (Calbiochem) in 50 mM Tris-Cl, pH 7.8, 100 mM NaCl, and 5 mM CaCl 2 for 2 h at 37°C. Laemmli sample buffer was added, and the sample was electrophoresed without heating on 10% SDS-polyacrylamide gel, followed by Western blotting with antibody 9E10 to visualize ADAMTS7B. In similar digests, Coomassie Blue staining was used after reducing SDS-PAGE to visualize ␣ 2 -macroglobulin. Processing of specific ADAMTS-susceptible peptide bonds in versican and aggrecan was analyzed using transfected HEK293F cells essentially as described previously (13) as well as in solution using the same volume of enzyme used in ␣ 2 -macroglobulin digests. Briefly, ADAMTS7B-transfected and ADAMTS4-transfected (as a positive control) cells were incubated in suspension culture with versican and aggrecan. Subsequently, aggrecan and versican were precipitated from the medium, deglycosylated, and analyzed by Western blotting using anti-neoepitope antibodies specific for the cleaved Glu 1771 -Ala 1772 and Glu 441 -Ala 442 peptide bonds of aggrecan and versican, respectively (13) . Cell lysates were analyzed by Western blotting with antibodies 9E10 and M2 to determine the expression levels of ADAMTS7B and ADAMTS4, respectively.
RESULTS
Primary Structure of ADAMTS7B-Shortly after the acceptance of our original publication on ADAMTS7 (18), a human cDNA (GenBank TM /EBI accession number AL110226, submitted August 13, 1999) that overlapped with our DNA sequence (accession number AF140675) at its C terminus was deposited by the German Cancer Research Center. Assembly of AF140675 and AL110226 resulted in a transcript that is 5338 bp in length and contains a polyadenylation signal (AUAAA) near the 3Ј-end. The mouse ADAMTS7B ORF was determined independently by cDNA cloning from a mouse muscle cDNA library. The human and mouse ADAMTS7B proteins are 1686 and 1641 amino acids long, respectively, with predicted masses of 181 and 178 kDa, respectively (excluding the signal peptide). The difference in length arises primarily within the prodomain and mucin domain. Fig. 1 demonstrates the conserved domain organization and noteworthy structural features of human and mouse ADAMTS7B. The previously described ADAMTS7 pro- tein (now designated ADAMTS7A) terminates in TSR2 (Fig. 1) . In ADAMTS7B, TSR2-8 are arranged in two arrays, with TSR4 and TSR5 separated by a polypeptide (420 amino acids long in human and 392 amino acids long in mouse) with sequence attributes typical of mucins, i.e. enrichment in Ser, Thr, and Pro residues, predicting heavy O-glycosylation. We refer to this as the mucin domain.
Human and mouse ADAMTS7B have high amino acid sequence homology (67% identity and 74% similarity, including conserved substitutions) and several potentially significant conserved sequence motifs (Fig. 2) . Three putative proprotein convertase (e.g. furin) recognition sites (RVLR 58 , RVLRKR 60 , and RQQR 220 , mouse sequence annotation) in human and mouse ADAMTS7B are at relatively conserved locations within the prodomain, implying similar activation sites and mechanisms. However, human ADAMTS7B has additional furin sites not present in mouse ADAMTS7B: RGRELR 92 , RRER 218 , RRPR 229 , and RLRR 232 . The zinc-binding active-site sequence is identical in both species (Fig. 2) . TSR1 contains tandem Trp-Ser-Xaa-Trp motifs that have been implicated in heparin and sulfatide binding of thrombospondin (25) . A Cys-Ser-ValThr-Cys-Gly motif that is suggested to mediate thrombospondin 1 binding to the CD36 receptor (26) is present at an identical location within TSR4 of human and mouse ADAMTS7B. Following prodomain processing at the most Cterminal furin-processing site, mature human and mouse ADAMTS7B are predicted to be 157.9 and 156.4 kDa, respectively. These calculations assume no further post-translational modification. However, both the human and mouse sequences predict considerable post-translational modification, including conserved potential GAG attachment sites ( 989 SGSG in mouse and 1006 SGSG in human) (27) within the mucin domain (Fig. 2 ).
FIG. 2-continued

ADAMTS7B Is a Proteoglycan
Gly-Ser dipeptides (Fig. 2 ) are also present within the mucin domain, some in appropriate sequence context for GAG attachment (27) , but they are not at identical locations in mouse and human ADAMTS7B. Of 10 N-linked glycosylation sites in human ADAMTS7B and nine in mouse ADAMTS7B, nine are at identical locations. Like many ADAMTS proteases (e.g. ADAMTS10, ADAMTS12, and ADAMTS16 -19), ADAMTS7B has a C-terminal PLAC (protease and lacunin) domain containing six cysteines in the expected arrangement ( Fig. 2) ), the zinc-binding active-site sequence, a putative heparin/sulfatide-binding motif in TSR1, and five N-linked glycosylation sites are conserved in these two proteases (Fig. 2) . ADAMTS12 has a putative CD36-binding motif, but it is located in TSR2 instead of TSR4 (ADAMTS7B) (Fig. 2) . ADAMTS12 has an additional putative proprotein convertase-processing site not found in ADAMTS7 (RFPDRR 41 ). Like ADAMTS7B, the primary structure of ADAMTS12 predicts a mucin domain separating TSR4 from TSR5, although this was not noted in a previous report (19) . According to our analysis, the ADAMTS12 mucin domain is considerably shorter (320 amino acids to 420 amino acids in human ADAMTS7B), accounting for much of the length discrepancy between ADAMTS7B and ADAMTS12. The mucin domains in ADAMTS7B and ADAMTS12 are rich in serines (46 residues each) and threonines (25 and 29 residues, respectively). ADAMTS7B has a higher percentage of prolines (18% in human and 17% in mouse) than ADAMTS12 (12%). Analysis of
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the ADAMTS7B and ADAMTS12 mucin domains at the NetOGlyc 2.0 Server (www.cbs.dtu.dk/services/NetOGlyc/) (29) predicts that 32 and 40 Ser ϩ Thr residues in the respective domains are likely to be O-glycosylated. The mucin domain in each enzyme contains a high number of acidic residues (12% and 11% Asp ϩ Glu residues in human ADAMTS7B and ADAMTS12, respectively) and has a net negative charge (human ADAMTS7B, Ϫ31.5; mouse ADAMTS7B, Ϫ43; and human ADAMTS12, Ϫ7.2 at pH 7.0). We have also detected two possible GAG attachment sites ( 1119 SGSG and 1156 SGSG) in the ADAMTS12 mucin domain, but they are located farther downstream of the corresponding sequences in ADAMTS7B (Fig. 2) . In addition, three Gly-Ser dipeptides and one Ser-Gly dipeptide are present in the ADAMTS12 mucin domain, but they are not conserved in human or mouse ADAMTS7B (Fig. 2) .
ADAMTS7B and ADAMTS12 have identical gene structures, each having 24 protein-coding exons with identical splice boundaries (Fig. 2) . ADAMTS7 maps to human chromosome 15q24 and spans 52.3 kb of genomic sequence, whereas ADAMTS12 maps to chromosome 5q35 (19) and spans 372 kb of genomic sequence. The catalytic site of each enzyme is interrupted by an intron, as in other ADAMTS genes such as ADAMTS9 (13) , with the exception of ADAMTS1 (30) . Each TSR is encoded by a single exon (except TSR1 and TSR2, which are encoded by two exons each), with the intron/exon boundary lying just upstream of the first cysteine residue of each repeat, a positioning similar to that in other ADAMTS family members (13) . The final exon of ADAMTS7 and ADAMTS12 encodes the PLAC domain. The largest exon of ADAMTS7 and ADAMTS12 encodes the entire mucin domain.
Origin of the ADAMTS7A Transcript Variant-ADAMTS7B diverges from ADAMTS7A (18) at a point in intron 16 that resembles a consensus splice donor site (Fig. 3A) . At this point, the ADAMTS7A ORF is contiguous with the genomic sequence and reaches a stop codon 190 bp downstream of the putative splice donor site. In contrast, at the point of divergence, the ADAMTS7B sequence is not continuous with the genomic sequence and is spliced into exon 17 (Fig. 3A) . As previously reported (18) , ADAMTS7A has a longer spacer domain than human or mouse ADAMTS7B or ADAMTS12. The extraneous region in the ADAMTS7A spacer domain is encoded by an intron (intron 14) that is included in the ADAMTS7A transcript and maintains the ORF from exons 14 to 15 (Fig. 3B) . In mouse, inclusion of this intron does not maintain the ORF
FIG. 2-continued
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(data not shown). The corresponding insertion is not present in ADAMTS12 (19) . ADAMTS7 Is Widely Expressed-Adamts7 expression was detected in mouse embryos as a single transcript of ϳ5.5 kb at gestational days 7, 11, 15, and 17 (Fig. 4A) . In adult human samples, ADAMTS7 expression was detected as a 5-kb transcript, with heart, pancreas, kidney, skeletal muscle, and liver having the highest level of expression (Fig. 4B) . In addition to ADAMTS7B Is a Proteoglycan 35166 the 5.5-kb transcript, a transcript of 8 kb and a prominent transcript of 4.5 kb were detected in skeletal muscle. Northern blotting using this probe produced results similar to those previously published using a probe common to both ADAMTS7A and ADAMTS7B (18), although we had not previously detected the 4.5-kb transcript in muscle.
ADAMTS7B Is Cell-associated-Western blotting of Myctagged mouse ADAMTS7B from serum-supplemented medium demonstrated that it migrated as two major bands, a broad and smeared band substantially greater than 250 kDa in size (referred to as the Ͼ250-kDa smear) and a sharper band just smaller than 250 kDa (referred to as the ϳ250-kDa band) (Fig.  5, A and B) . Each band was larger than the conceptual translation product (181 kDa). Treatment with 0.5 M NaCl released additional ADAMTS7B from cells (Fig. 5B) . This result indicates that ADAMTS7B is secreted, but is partially, transiently, or loosely retained in the pericellular region by interaction with one or more molecules at the cell surface or in the pericellular matrix. To confirm that the ADAMTS7B released by treatment with 0.5 M NaCl originated from the cell surface and not from an intracellular pool, we undertook biotinylation of cell-surface proteins. Cells in suspension were briefly treated with trypsin (to eliminate all surface proteins as a negative control) or with serum-free medium 15 min prior to biotinylation. After biotinylation, proteins were salt-eluted and captured with streptavidin-agarose. Untrypsinized cells had a biotin-labeled ϳ250-kDa anti-c-Myc antibody-immunoreactive band corresponding to ADAMTS7B (Fig. 5C ), but not the Ͼ250-kDa smeared species. In contrast, samples from the trypsinized cells contained no biotinylated anti-c-Myc antibody-immunoreactive bands (Fig. 5C ), but lysates of these cells were positive for ADAMTS7B by Western blotting (data not shown). This indicates that ADAMTS7B is external to the cell membrane, and since HEK293F cells do not make an appreciable amount of ECM, it is likely to be in close proximity to the cell membrane.
Proteolysis of ADAMTS7B in Serum-free Medium-There was no detectable proteolysis of ADAMTS7B when analyzed in cells grown in serum-supplemented medium (Fig. 5A) . However, analysis of the ADAMTS7B from serum-free medium demonstrated fragmentation of the protein, presumably proteolytic, with additional anti-c-Myc antibody-immunoreactive bands being generated (Fig. 5, B, D, F, and G) . The major anti-c-Myc antibody-reactive fragments observed were ϳ120 and 40 kDa in size. Both bands showed more rapid in-gel migration after PNGase F treatment (Fig. 5D) , indicating that they contained N-linked carbohydrate. The ϳ120-kDa fragment, but not the ϳ40-kDa band, was more prominent following chondroitinase digestion and was recognized by antibody 2035 (Fig. 5E) , suggesting that the 120-kDa fragment bears the chondroitin sulfate (CS) chain.
Secreted ADAMTS7B Is Post-translationally Modified and Has an Attached Chondroitin Sulfate Chain-Since the mouse ADAMTS7B sequence predicts eight potential N-linked glycosylation sites, we treated it with PNGase F to remove N-linked sugars. The ϳ250-kDa ADAMTS7B band thus treated migrated faster on Western blots, indicating the presence of Nlinked sugars, but the migration of the Ͼ250-kDa smear was largely unaffected by PNGase F (Fig. 5D ).
Upon treatment with chondroitinase ABC, but not with keratanases or heparinases, the Ͼ250-kDa smear largely disappeared; and instead, the amount of enzyme migrating at ϳ250 kDa increased substantially, indicating conversion of a CSsubstituted protein to the core protein form (Fig. 5E) . However, the presence of a faint new immunoreactive protein band following keratanase digestion (Fig. 5E ) might be indicative of some keratan sulfate substitution as well. Furthermore, the chondroitinase ABC-digested core protein, but not the native protein from these cells, was immunoreactive with a monoclonal antibody (2035) recognizing CS stubs (Fig. 5E ). Chondroitin sulfate modification was seen following transient transfection into COS-1 (Fig. 5F ) and CHO-K1 (Fig. 5G ) cells as well. A CHO cell mutant (CHO-K1 pgsA-745) with diminished xylosyltransferase produced primarily the ϳ250-kDa form and lacked the Ͼ250-kDa smear seen in the parental CHO-K1 cell line that represented the CS-modified form (Fig. 5G) .
To verify that the mucin domain was indeed heavily Oglycosylated and modified by CS chain attachment, we expressed the mouse ADAMTS7B mucin domain alone with an N-terminal FLAG tag as a secreted protein using the preprotrypsin leader sequence (Fig. 6A) . Instead of the expected molecular mass of 37 kDa, the expressed protein migrated as broad bands of 50 and 75-and a smear of Ͼ100 kDa (Fig. 6B ). When treated with chondroitinase ABC, the smear disappeared, and the 50-kDa band was accentuated (Fig. 6B, upper  panel) , suggesting conversion of CS-modified protein. The resulting chondroitinase-digested 50-kDa band was reactive with monoclonal antibody 2035, confirming the presence of a CS chain in the mucin domain (Fig. 6B, lower panel) . Since the expressed mucin domain contains only one N-linked glycosylation site, we considered the increase in mass of ϳ13-40 kDa to be a consequence of O-glycosylation. Accordingly, horseradish peroxidase-conjugated peanut agglutinin bound to the 75-kDa band in ligand blot experiments (Fig. 6C) , but not to ADAMTS7 PRO-CAT-Myc/His (as a negative control). The 75-kDa band was only moderately altered by digestion with sialidase and O-glycosidase (data not shown), suggesting that the majority of the O-linked sugars were not capped with terminal sialic acid residues.
CS-modified ADAMTS7B Does Not Bind Heparin-To investigate whether ADAMTS7B binds heparin and whether binding is influenced by the GAG chain, the medium from HEK293 cells expressing full-length mouse ADAMTS7B was batch-incubated with heparin-Sepharose. Following elution of beads with 0.5 M NaCl (data not shown), the majority of ADAMTS7B remaining bound to heparin-Sepharose was ϳ250 kDa in size, with relatively little of the CS form being evident (Fig. 6D) . On the other hand, acetone-concentrated protein from the unbound fraction of the medium showed the CS-substituted species as the majority, with very little of the ϳ250-kDa form (Fig.   FIG. 4 . 
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6D), indicating that the CS form had relatively poor affinity for heparin-Sepharose. The 150-and 75-kDa bands found in the unbound fraction may have been proteolytically derived.
ADAMTS7 PRO-CAT-Myc/His Is Sequentially Processed by Proprotein Convertases-SDS-PAGE of His-tagged proteins from
human or mouse ADAMTS7 PRO-CAT-Myc/His -expressing HEK293 cells demonstrated two major protein bands of ϳ50 and 29 kDa on Coomassie Blue-stained gels, with several quantitatively minor intermediate bands (Fig. 7A) . Western blotting using anti-c-Myc antibody demonstrated that these bands correspond to major forms of ADAMTS7 PRO-CAT-Myc/His (Fig. 7B) . The amino acid sequences of the 50-and 29-kDa major bands obtained by Edman degradation are 61 DVSTTQ and 221 SVSKEK, respectively, indicating processing following Arg 60 (designated the initial processed or P1 form) and Arg 220 (designated the final processed, mature, or M form) (mouse sequence annotation), respectively (Fig. 7B) . Because the human and mouse sequences around the most C-terminal furin-processing site do not align perfectly, we obtained the N-terminal sequence of the 29-kDa human ADAMTS7 PRO-CAT-Myc/His band as well. It was 237 SVSKEKW, similar to that of mouse, indicating processing following Arg 236 . PNGase F digestion enhanced migration of the 50-kDa P1 band, but not of the 29-kDa M band, in keeping with the absence of consensus N-linked sites in the catalytic domain and the presence of a single N-glycosylation site in the prodomain (Fig. 7C ). In the cell lysate, but not in the medium, a doublet of ϳ50 kDa was noted (Fig. 7C) , presumably corresponding to either the signal peptide processed (zymogen or Z form) and Arg 60 processed forms or the Arg 58 and Arg 60 processed forms.
Cell-surface biotinylation was done with HEK293F cells transfected with mouse ADAMTS7 PRO-CAT-Myc/His . Although biotinylated 50-and 29-kDa bands were found in the medium of these cells, the biotinylated 50-kDa P1 form was the major species detected on the surface of cells (Fig. 7D) . To clarify this apparent discrepancy, we first biotinylated cell-surface proteins and then tracked biotinylated mouse ADAMTS7 PRO-CAT-Myc/His in the medium for up to 3 h. In control experiments, cells were treated with trypsin prior to biotinylation to demonstrate that the biotinylated proteins were of cell-surface and not intracellular origin (Fig. 7D) . The results show that the 50-kDa P1 form was progressively converted to a soluble 29-kDa M form, with an intermediate 35-kDa form (Fig.  7E) , suggesting that processing from the 50-kDa P1 form to the 29-kDa M form occurs at the cell surface, with subsequent release of the 29-kDa M species. However, no 29-kDa M form was found in lysates of biotinylated cells (Fig. 7E) , suggesting that its release from the cell surface occurs immediately after the final processing event. The origin of the 35-kDa species (intermediate processing form) is uncertain since there is not a consensus furin-processing site between Arg 60 and Arg 220 that accounts for it, although the size of the intermediate and its inhibition by decanoyl-RVKR chloromethyl ketone (Fig. 8D ) suggest processing at an as yet unknown processing site such as ETRR 102 . In addition, since the 50-kDa species could be biotinylated on the cell surface, this suggests an interaction of the prodomain with some unknown moiety on the cell membrane, possible furin itself (31) .
Three putative proprotein convertase recognition sequences are located in mouse ADAMTS7B and seven in human ADAMTS7B. The mouse ADAMTS7 PRO-CAT-Myc/His molecular species derived from processing are illustrated in Fig. 8A . Nterminal sequence analysis suggested that two of these sites are preferentially processed in human and mouse ADAMTS7 (Fig. 7B) , but did not indicate the order in which this might occur or the time course of activation. Accordingly, transient transfection of mouse ADAMTS7 PRO-CAT-Myc/His in QBI 293A cells was followed by metabolic labeling with [ 35 S]methionine/ cysteine using a pulse of 15 min, followed by a chase of the radiolabeled protein in cells and medium for up to 120 min.
Radiolabeled ADAMTS7 protein was first detected in the culture medium after a chase of 30 min, and the amount of the labeled protein in cells decreased after 60 min (Fig. 8B) . The 29-kDa M form first appeared in the medium after a 60-min chase. The 50-kDa P1 form accumulated in the medium from 30 to 120 min, but the 29-kDa M form did not, possibly as a consequence of rapid turnover by autocatalysis.
CHO RPE.40 cells, which are furin-deficient, were unable to proteolytically process ADAMTS7 PRO-CAT-Myc/His (Fig. 8C, upper panel) . To determine which proprotein convertases could process ADAMTS7B, we cotransfected CHO RPE.40 cells with mouse ADAMTS7 PRO-CAT-Myc/His and furin, PACE4, PC6B, or PC7. Analysis of the media of these transfected cells revealed that furin was able to process ADAMTS7 PRO-CAT-Myc/His completely to the mature form (Fig. 8C, upper panel) . Interestingly, the cell lysate showed both the 50-kDa P1 form and the 29-kDa M form, whereas the medium contained only the 29-kDa M form. PC6B and PC7 processed ADAMTS7 PRO-CAT-Myc/His , but the medium contained the 54-kDa Z form as well as the P1 and M forms, indicating that they inefficiently processed ADAMTS7 to its mature form. Interestingly, PACE4 showed predominantly the 54-kDa Z band in the medium, indicating a failure of this enzyme to utilize any of the furin sites within the prodomain of ADAMTS7. To ascertain which of the Arg 60 and Arg 220 furin sites was indispensable for zymogen maturation, we obtained site-directed mutants in which the P1 Arg residue was mutated to Ala. Expression of these forms in QBI 293A cells demonstrated that when Arg 60 was mutated, processing occurred instead at an adjacent alternative site (RVLR 58 ) since a slightly decreased migration of the 50-kDa P1 band was noted (Fig. 8C, lower panel, asterisk) , and complete processing to the 29-kDa M form was also noted. On the other hand, when Arg 220 was replaced by Ala, only the 50-kDa P1 band was noted, and the 29-kDa M form was absent in the medium. Although Nterminal sequence analysis suggests that Arg 60 is preferred, these experiments suggest that when this site is unavailable, Arg 58 can be used. Taken together, these data suggest a scenario in which furin is the preferred pro-ADAMTS7B convertase and that it may operate at two locations in the cell to sequentially produce the P1 and M forms. The data suggest that the processing event that produces the M form occurs at the cell surface through a 35-kDa intermediate. To further investigate this, we treated HEK293 cells expressing ADAMTS7 PRO-CAT-Myc/His with increasing concentrations of the synthetic furin inhibitor decanoyl-RVKR chloromethyl ketone. At low concentrations (10 M), it inhibited processing to the 35-kDa intermediate and the M form, but only partially inhibited processing to the 50-kDa form (Fig. 8D) . Since this lipophilic inhibitor will permeate cells, higher concentrations (Ն25 M) completely inhibited processing to the P1 and smaller forms, and only the zymogen was apparent (Fig. 8D) .
ADAMTS7B and ADAMTS7 PRO-CAT-Myc/His Are Functional Proteinases-ADAMTS7B was demonstrated to be catalytically active using the broad-spectrum protease substrate and inhibitor ␣ 2 -macroglobulin (32). ␣ 2 -Macroglobulin, a serum protein, is a circulating endoproteinase inhibitor that is commonly used as a nonspecific protease substrate. Cleavage by many proteases within a proteolytically susceptible "bait" region results in engulfment of the protease and is frequently followed by formation of an irreversible complex. Thus, anomalous migration of a protease upon incubation with ␣ 2 -macroglobulin is considered evidence of proteolytic activity. ADAMTS7 PRO-CATMyc/His and ADAMTS7B were both able to cleave ␣ 2 -macroglobulin as shown by altered migration of the protease on SDSpolyacrylamide gel (Fig. 9, A and B) and proteolysis of ␣ 2 -macroglobulin by SDS-PAGE (Fig. 9C) . However, using antineoepitope antibodies to detect specific ADAMTS cleavage products of aggrecan and versican (12, 33) , ADAMTS7B digestion did not reveal the target epitopes (data not shown), suggesting that it does not attack these sites. In these experiments, equivalent amounts of ADAMTS7B that cleaved ␣ 2 -macroglobulin were used. ADAMTS7B-transfected cells did not process aggrecan either, whereas ADAMTS4-transfected cells did, despite the ADAMTS7 expression level being considerably higher compared with the ADAMTS4 expression level (Fig.  9D ). In combination, these studies demonstrate that ADAMTS7B could not process aggrecan in cells even at much higher levels compared with ADAMTS4 and in solution at levels at which it could cleave ␣ 2 -macroglobulin. FIG. 6 . Characterization of the ADAMTS7B mucin domain (ADAMTS7B FLAG-MUC ) and heparin binding of full-length ADAMTS7B. Unless specified, Western blotting was performed with anti-FLAG monoclonal antibody M2. A, schematic of ADAMTS-7B FLAG-MUC using the symbols shown in Fig. 1 . B, chondroitinase ABC (CABC) digest of ADAMTS7B FLAG-MUC (ϩ) showing attenuation of the broad ϳ100-kDa smear present in the undigested (Ϫ) control (upper panel). Chondroitinase-digested ADAMTS7B FLAG-MUC subsequently reacted with monoclonal antibody 2035 (MAB2035; lower panel). C, peanut agglutinin ligand blot. Horseradish peroxidase-conjugated peanut agglutinin bound to 75-kDa ADAMTS7B FLAG-MUC , but not to ADAMTS7 PRO-CAT-Myc/His . D, binding of ADAMTS7B to heparinSepharose. From a mixture of CS-modified and -unmodified ADAMTS7B present in unconcentrated conditioned medium (Prebinding), the CS-unmodified form (ϳ250 kDa) was enriched by incubation with heparin-Sepharose (Bound). The CS-modified ADAMTS7B smear (Ͼ250 kDa) did not bind to the heparin-Sepharose beads (Unbound; acetone-precipitated medium after heparin-Sepharose binding). Western blotting was performed with antibody 9E10.
DISCUSSION
The existence of putative ADAMTS7B has been readily apparent by data base analysis since 1999, and its domain organization has been previously noted in the literature (34, 35) and in online resources (www.lerner.ccf.org/bme/apte/adamts/). We have now confirmed by cDNA cloning in the mouse that ADAMTS7B mRNA does exist in tissues. Several considerations suggest that ADAMTS7B encodes the full-length product of the ADAMTS7 gene and that ADAMTS7A represents an incompletely processed mRNA with retention of two introns. Analysis of expressed sequence tags in the GenBank TM /EBI Data Bank validated the sequence of ADAMTS7B, but no expressed sequence tag with the 3Ј-sequence of ADAMTS7A was found. Incidentally, intron retention confounded the initial characterization of ADAMTS6, ADAMTS9, ADAMTS16, and ADAMTS18 (18, 36, 37) , and longer ORFs have subsequently been identified (13) . 3 The ADAMTS7A transcript is unlikely to be an alternatively spliced product. It lacks a polyadenylation signal, and the ORF shift in TSR2 has at best a superficial resemblance to other TSR sequences. All other TSRs in ADAMTS proteases have six cysteines, and their spacing and intervening amino acids are quite different from those of TSR2 in ADAMTS7A, which has seven cysteines. Similarly, we do not believe that the longer ADAMTS7 spacer sequence we originally described is authentic since the corresponding intron inclusion in mouse ADAMTS7B truncates the reading frame.
On the basis of identical domain organization and highly similar primary sequence and intron/exon structure, ADAMTS7B and ADAMTS12 clearly form a new phylogenetic clade in the ADAMTS family. It is probable that these genes arose from a gene duplication event. The active-site motifs in ADAMTS7B and ADAMTS12 are identical to each other, but not to other ADAMTS proteases. This is highly suggestive of a conserved biochemical function distinct from that of other ADAMTS proteases. Consistent with this, ADAMTS7B could not process aggrecan or versican at specific peptide bonds that are attacked by ADAMTS1, ADAMTS4, ADAMTS5, and ADAMTS9, which are on different evolutionary branches of the ADAMTS family tree (34) . Nevertheless, ADAMTS7B is an active protease since both the full-length enzyme and ADAMTS7 PRO-CAT-Myc/His cleaved ␣ 2 -macroglobulin.
Unlike the ADAM proteases and membrane-type matrix metalloproteases, ADAMTS proteases do not contain transmembrane segments or glycophosphoinositol signal anchor sequences. However, cell-surface biotinylation demonstrated that ADAMTS7B localized to the cell surface and was released at elevated salt concentrations. Localization at the cell surface has been previously shown for ADAMTS1 (24) , ADAMTS4 (13, 38, 39) , and ADAMTS9 (13) and likely occurs via an ionic interaction with a cell-surface or pericellular matrix molecule. Cell-surface interaction of these proteases is mediated by their ancillary domain (13, 38) . Since fully activated ADAMTS7 PRO-CAT-Myc/His was not present at the cell surface, we conclude that the ADAMTS7B ancillary domain mediates its binding to the cell surface. The putative CD36-and heparin/sulfatide-binding motifs in the ancillary domain are possible motifs by which binding of the full-length active enzyme may occur. In support of the latter possibility, ADAMTS7B bound heparin-Sepharose. Since localization of the 50-kDa form of ADAMTS7 PRO-CAT-Myc/His at the cell surface was followed by furin activation, we surmise that it may be retained at the cell surface through interaction of the prodomain with furin. Thus, the ADAMTS7B zymogen is retained at the cell surface through interactions involving both the prodomain and ancillary domain, whereas the mature enzyme is retained through interactions involving the ancillary domain alone. A unique feature of ADAMTS7B that sets it apart from all other ADAMTS proteases, with the likely exception of ADAMTS12, is the presence of a putative mucin domain. Interestingly, like the mucin domain of syndecan-3 (40), it is entirely encoded by one exon, implying its introduction by exon shuffling during evolution. Although it is smaller than that in ADAMTS7B, the putative ADAMTS12 mucin domain contains comparatively more predicted O-glycosylation sites and a conserved N-glycosylation site. What are the functional implications of this substantial post-translational modification? The mucin domain is expected to have an extended conformation and to function as a stalk or rigid spacer between the two TSR arrays in ADAMTS7B. It may also have a role in protecting this region from proteolysis (41) . In platelet glycoprotein-1B␣, the mucin-like region is required for cell adhesion to immobilized von Willebrand factor (42) ; and in neutral ceramidase, the mucin-like region facilitates cell membrane localization (43) . It could also affect proteolytic specificity since recent studies have shown that glycosylation of MMP14 affects its substrate profile (44) .
The mucin domain is further modified by addition of one or more CS chains. The poorly resolved in-gel migration of the Ͼ250-kDa smear prompted us to ask whether there was GAG attachment to ADAMTS7B. In three unrelated cell types, ADAMTS7B bears one or more CS chains, suggesting that when modified, it may be an obligatory chondroitin sulfate proteoglycan. However, we cannot exclude the possibility that other cell types may attach a heparan sulfate chain to the acceptor site since the attachment of both GAGs occurs through the carbohydrate primer region Xyl-Gal-Gal-GlcA and at broadly similar acceptor sequences on the core protein (45) . Some proteoglycans such as perlecan and syndecan-1 have a hybrid GAG substitution containing both CS and heparan sulfate chains (45, 46) . ADAMTS7B could be a part-time chondroitin sulfate proteoglycan, existing in both GAG-substituted and GAG-free forms. Our studies in COS-1 and HEK293 cells support this, although it is possible that high expression levels in transfected cells may allow partial escape from GAG substitution. Although we demonstrated CS chain attachment within the mucin domain, the precise site(s) of GAG attachment and the number of GAG chains are presently undetermined. Comparison of a number of GAG acceptor sequences has shown that the acceptor site is often Ser-Gly-Xaa-Gly (with the Ser residue accepting the initiating xylosyl) and is frequently in the immediate vicinity of acidic residues (27) . Both requirements are met at the proposed ADAMTS7B GAG attachment motifs. The Gly- Ser 1061 (mouse), Gly-Ser 1108 (mouse), and Gly-Ser 1324 (human) dipeptides present in the mucin domain also have one or more acidic residues in the immediate vicinity and could support GAG attachment. Of two putative Ser-Gly-Ser-Gly sequence motifs in the putative human ADAMTS12 mucin domain, one (Ser 1158 ) lies within a very acidic amino acid context that may favor substitution with heparan sulfate (45) . GAG attachment of ADAMTS12 is presently unresolved since the data in a previous study of ADAMTS12 (19) did not include the upper reaches of the gel. We are addressing the possible attachment of a GAG chain to ADAMTS12 in ongoing studies. GAG attachment is rare in proteolytic enzymes. It has potential regulatory significance since it could influence affinity for ligands and substrates and affect compartmentalization of ADAMTS7B. Indeed, when affinity-purified by heparin-Sepharose chromatography, the dominant ADAMTS7B form captured on the matrix was the GAG-unsubstituted form, and biotinylation experiments indicated that the major species present near the cell surface lacked the CS chain. Important functions have been shown for GAG chains in other proteoglycans. In Nudel, a Drosophila protease, the GAG chain is essential for its proteolytic activity and for dorsoventral patterning (47) . The B16F10 cell receptor for a metastasis-promoting laminin-1 peptide is a hybrid CS/heparan sulfate proteoglycan that requires the GAG chain for the metastasis-promoting activity of the peptide (48) . In future studies, we will study the fine structure and regulatory role of the GAG chain(s) in more detail.
Proteolysis within the ancillary domain is another potentially significant post-translational event. Western blotting detected two major smaller anti-c-Myc antibody-immunoreactive bands that we estimate to have been produced by proteolysis within the disintegrin-like domain and the C terminus of the mucin domain, respectively. Interestingly, these fragments were not seen in serum-supplemented medium, possibly due to endogenous inhibitors in the serum such as ␣ 2 -macroglobulin, shown here to be an ADAMTS7B substrate. The proteolytic fragmentation of several ADAMTS enzymes, including ADAMTS1 (16), ADAMTS4 (39, 49) , ADAMTS9 (13) , and ADAMTS12 (19) , has been reported. C-terminal processing of ADAMTS4 appears to be important in regulating its substrate profile (39, 49) . In addition to affecting protease activity, it is tempting to speculate that the released 120-and 40-kDa fragments might have independent biological activities or might competitively inhibit proteolysis by ADAMTS7B. These possibilities can be tested once ADAMTS7B substrates are identified.
Consistent with their forming a distinct clade, ADAMTS7B and ADAMTS12 proprotein convertase sites are situated at similar locations. Proprotein convertases are subtilisin-like, calcium-dependent serine proteases present in the Golgi apparatus or at the cell surface that attack well defined recognition sequences containing dibasic or tetrabasic residues (50, 51) . In this work, we have shown that conversion to the mature ADAMTS7 enzyme did not occur in the absence of furin. PC6B and PC7 processed pro-ADAMTS7B less efficiently than furin, whereas PACE4 could not process pro-ADAMTS7B. The emphasis on furin, PACE4, PC6, and PC7 in this study is reflective of widespread distribution observed for ADAMTS7 in tissues. 4 Indeed, all aforementioned convertases have a ubiquitous (furin) or widespread expression in contrast to convertases such as PC1, PC2, and PC4, which are specifically localized only in endocrine/neuroendocrine cells or testicular germ cells (48) . In view of the ubiquitous expression and efficient processing of ADAMTS7B, furin is probably its physiological convertase in most cells and organs (50, 51) . N-terminal sequencing demonstrated that only two of three putative cleavage sites are preferred in mouse ADAMTS7, but site-directed mutagenesis suggested that Arg 58 can be used as an alternative to Arg 60 . The N terminus of mature ADAMTS7B corresponds closely to the position of the N termini of mature ADAMTS1, ADAMTS2, ADAMTS4, ADAMTS9, and ADAMTS13 (9, 13, 14, 52, 53) . Many ADAMTS proteases such as ADAMTS4, ADAMTS9, and ADAMTS20 have multiple furin-processing sites in their prodomains (13, 54) , yet final processing appears to occur at the most C-terminal one, as noted here for ADAMTS7B.
The ␣ 2 -macroglobulin assay suggested that Arg 60 processed mouse ADAMTS7 PRO-CAT-Myc/His , which retains most of the prodomain, is catalytically active since the mobility of this form was altered in the presence of ␣ 2 -macroglobulin. It was recently shown that the ADAMTS13 zymogen is catalytically competent (55) . ADAMTS13 has an unusually short prodomain and is very different from other ADAMTS proteases (55) . The proteolytic activity present in the zymogen of ADAMTS7B, an enzyme with a typical prodomain, suggests that it may have an accessible active site and that the cysteine-switch mechanism of matrix metalloprotease zymogen activation (56) , in which an unpaired cysteine in the prodomain ligands the active-site zinc atom, may not be operative in this enzyme and ADAMTS13. The reason for the apparent loss of ADAMTS7 PRO-CAT-Myc/His in the presence of ␣ 2 -macroglobulin is unclear, but may be related to inefficient migration or electroblotting of the enzyme⅐␣ 2 -macroglobulin complex.
The experimental observations from radioactive precursor and biotin pulse-chase experiments, furin inhibition, and protein sequencing together support a multistep model of ADAMTS7B zymogen processing (Fig. 10 ). In this model, newly synthesized ADAMTS7B is first efficiently clipped intracellularly by furin following Arg 60 or Arg 58 . Subsequently, this form is processed by furin following Arg 220 . Furin inhibition studies indicated that the processing event at Arg 220 was sensitive to lower concentrations of furin inhibitor compared with the processing event at Arg 60 , suggesting that it is more easily accessible to the inhibitor, i.e. it may occur at the cell surface or late in the secretory pathway. In contrast, the Arg 60 processing event occurred early in the secretory pathway and required higher concentrations for inhibition. Since the 50-kDa P1 form was retained at the cell surface, the Arg 220 -Ser bond may be attacked less efficiently than the Arg 60 -Ser bond, and this processing event may be rate-limiting for the release of fully active enzyme. This could be a consequence of there being considerably more intracellular than cell-surface furin (57) . Accordingly, when furin was overexpressed in cells along with ADAMTS7, there was complete processing to the 29-kDa M form. However, when ADAMTS7 was expressed without commensurately high expression of furin (as in most of our processing experiments), the processing mechanism at the cell surface was overwhelmed, and there was release of both fully processed (i.e. at Arg 220 ) and incompletely processed (at Arg 60 ) ADAMTS7. Even when there was excess ADAMTS7, the initial processing at Arg 60 was complete, and the signal peptide processed ADAMTS7 zymogen was not released from the secretory pathway. A two-step activation mechanism has also been proposed for ADAMTS2 through similar approaches (58), although it is unclear if the final processing occurs at the cell surface.
Within the ADAMTS family, there are a number of distinct clades in which structurally identical proteases such as ADAMTS7B and ADAMTS12 appear to have evolved by gene duplication (13) . An intriguing possibility is that such homologs have similar biochemical and catalytic properties, but they are differently regulated, and that it is differential gene regulation that may underlie distinctive biological roles of homologs rather than variations in intrinsic properties. In this context, it will be important to investigate whether ADAMTS12 is also a CS-or heparan sulfate-modified mucin domain-containing enzyme and to contrast the gene regulation and substrate profile of these two enzymes.
